Tagged autologous hematopoietic stem cell transplant, chemotherapy, grey matter, serum neurofilament light chain, Stem Cells. sNfL has been proposed as a marker of neuron degeneration and damage, and sGFAP is a marker of astrocytes, cells involved in the provision of nutrients to neurons, the repair of nervous tissue following injury, and in facilitating neurotransmission (essential in nerve cell communication).

that contains melphalan. High-dose chemotherapy and stem cell transplantation are important parts of treatment plans for eligible, recently diagnosed myeloma patients. Autologous Stem Cell Transplantation. Be the first to rate this post. Please check with your financial advisor if you have more questions. reduced-intensity allogeneic transplantation, Blood and Marrow Stem Cell Transplantation, Stem Cell Transplantation with High-Dose Chemotherapy, https://www.lls.org/content/contact-us?UID=LLS-26-756. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Tandem Autologous Stem Cell Transplantation. In Canada, the chemotherapy regimen used in clinical practice is particularly intense and involves high doses of two agents, cyclophosphamide and busulfan.

Chemo and radiation side effects can make you sick, and it may take you months to fully recover.

We are very sorry no one was available to take your chat at this time. During this procedure stem cells are collected from the patient, the patient is then treated with high doses of chemotherapy, often using melphalan. Stem cell transplants -- from bone marrow or other sources -- can be an effective treatment for people with certain forms of cancer, such as leukemia and lymphoma. In an autologous stem cell transplant, a patient’s own blood stem cells are collected several times in the weeks before treatment.

Stem cell transplants differ based on whom the blood-forming stem cells come from. “This study is the first to correlate these increases [rises in brain atrophy and serum markers of neurotoxicity] with doses of chemotherapy administered” in aHSCT, they added. In these cases, the transplant can help treat certain types of cancer in a way other than just replacing stem cells. During this procedure stem cells are collected from the patient, the patient is then treated with high doses of chemotherapy, often using melphalan.

To test these interpretations, a team led by researchers at the University of Ottawa measured the levels of two markers — serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) — in the blood (serum) of MS patients before and after the chemotherapy regimen in aHSCT. Patients given the highest dose of busulfan (more than 700 mg) had the highest levels of sNfL and a greater extend of grey matter loss, shown by MRI, at three months post-treatment. It does not produce the neurotoxicity of other immunomodulatory drugs. Three months after aHSCT, levels of sNfL significantly increased by 32.1% (from 21.8 to 28.8 pg/mL), and sGFAP levels by 74.8% (from 107.4 to 187.7 pg/mL) in 15 patients with available three-month data, compared to their pre-treatment levels. It does not provide medical advice, diagnosis or treatment. More information is needed about the effects of maintenance therapy on overall survival, as well as second cancer risk. for post-transplant maintenance, based on the results of several clinical trials. Thank you. Pensacola, FL 32502 This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. No votes so far! Please note, our regular chat hours are Monday-Friday, 10AM to 7PM Eastern Time.

Further analysis looked at changes from baseline (study start) and three-month post-aHSCT measures of sNfL levels and grey matter volume loss. Phone: 1-800-936-1363.

LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. The result is a “transient worsening of post‐treatment EDSS score as well as MRI volume loss, especially in the grey matter,” the researchers wrote. This was interpreted as a false (pseudo) shrinkage of brain volume due to lesser inflammation.